A Multi-center 12-week Study of HMS5552 in T2DM
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 258 participants.
Also called NCT02561338
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 258 participants
- Registry
-
NCT02561338
-
- Other papers using this trial's data
- Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02561338. Randomized; quadruple masking; primary purpose treatment. Start 2015-09 (registry gives no type); primary completion 2016-09 (actual). Results posted on 2020-03-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Multi-center 12-week Study of HMS5552 in T2DM
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- HMS5552
- Intervention (Drug)
- HMS5552
- Intervention (Drug)
- HMS5552
- Intervention (Drug)
- HMS5552
- Intervention (Other)
- Placebo
- Lead sponsor
- Hua Medicine Limited
- Collaborator
- Tigermed Consulting Co., Ltd
Record details
- Record id
cardio:ct-nct02561338- Content hash
2d182d2c88aa42fe07c10d64c9cfc915c77dfe766afe9da3f3f601c2f34b734c